Navigation Links
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Date:6/17/2008

rial in mid-2008 for the treatment of cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About BioInvent

BioInvent International AB, listed on The Nordic Exchange (OMXS:BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer, atherosclerosis and ophthalmic diseases. In January 2007 the Company announced a major strategic alliance with American-based Genentech, Inc. in the cardiovascular field. These projects are based on a competitive and in substance patented technology platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abelló, ImmunoGen, OrbusNeich, Sanofi-Aventis, UCB and XOMA.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharm
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014  LABSCO, the leading specialty sales ... hospitals, physician office laboratories and alternate healthcare settings ... 2014, it will serve as Siemens Healthcare Diagnostics, ... and as a semi-exclusive sales distributor in specified ... United States . LABSCO will be ...
(Date:9/16/2014)... , Sept. 16, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  The full interim results will be ... GRS and IGF Society, being held October 15-18, ...
(Date:9/16/2014)... BCC Research reveals in its ... , the global market for stem cells is expected ... a five-year compound annual growth rate (CAGR) of 13.6%. ... with growth projections of $2.2 billion in 2014 to ... , Unlike other potential applications of bioscience, ...
(Date:9/16/2014)... RENU 28, the world's first and only skin gel ... in Australia and New Zealand in mid-August . , The ... tour will make stops in Brisbane on September 16, the ... on the 20th, and Melbourne on the 22nd. , Helping ... to educate people about the new product and business opportunity ...
Breaking Biology Technology:LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2
... led by Governor Doyle and organized by Forward Wisconsin ... industrys leading conference with goals to establish new partnerships, ... community and to let others know that Wisconsin has ... group, the delegation met its objectives in spite of ...
... Medical Systems, a unit of General Electric Company, announced ... Food and Drug Administration to begin marketing its new ... Signa EXCITE 3.0T combines the increased speed and higher ... of imaging capabilities found on premium 1.5 Tesla systems. ...
... Insurance. Motorcycles? Computerworld has just released their ... 2003, and five Wisconsin companies have placed in the ... Inc. of Milwaukee. , ,This years list, with ... employees perspectives of working conditions and employment benefits. According ...
Cached Biology Technology:On site at BIO 2003 2On site at BIO 2003 3On site at BIO 2003 4On site at BIO 2003 5GE Medical Systems Receives FDA Clearance for New MRI System 2Wisconsin Companies Ranked Top in Nation in IT 2Wisconsin Companies Ranked Top in Nation in IT 3Wisconsin Companies Ranked Top in Nation in IT 4
(Date:9/16/2014)... Spanish . CRG ... the Journal of Cell Biology describes how Topo ... division , At this very moment thousands of our body,s ... which the body repairs damaged tissues and regenerates others like ... as "mitosis", during which the cell duplicates its genetic material ...
(Date:9/16/2014)... vital functions in an organism. For example, they ... and control immune system responses. Researchers established some ... of each other, but instead form complex networks. ... find many similarities with online social networks," says ... Systems Biology. "Some proteins are good networkers that ...
(Date:9/16/2014)... , Sept. 16, 2014 As open ... make important decisions about their 2015 benefits. According to ... health solutions business of Aon plc (NYSE: ... take a more proactive role in managing their health ... than ever for individuals to understand how they can ...
Breaking Biology News(10 mins):Unraveling cell division 2Unraveling cell division 3Good networkers make prime targets 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 3Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 4Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 5Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 6Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 7
... , EAST LANSING, Mich. Bacteria infections most of ... world and not malaria are the leading cause of ... new Michigan State University project based in Nigeria and funded ... diseases by collecting local data on the ailments, spurring vaccine ...
... European Molecular Biology Laboratory (EMBL) in Monterotondo, is one ... honoured with a Howard Hughes Medical Institute (HHMI) International ... for five years, is designed to give a boost ... United States. The award recognises the potential of Sotillo,s ...
... concern that excessive levels of fructose may pose a great health ... researchers at the University of Colorado School of Medicine, along with ... if two common sweeteners in western diets differ in their effects ... The study, recently published in the journal Metabolism , took ...
Cached Biology News:$5.8 million Gates grant targets child-killing bacteria diseases in Africa 2CU School of Medicine researchers look at effects of 2 common sweeteners on the body 2
Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
...
... Kit Includes: Sufficient library for ... x 10^9 independent sequences, -28 gIII ... DNA sequencing, -96 gIII Sequencing Primer ... Host E. coli strain ER2738, Control ...
... The CHEMICON Re-Blot Western Blot Recycling ... antibodies from Western blots that have ... iodine or other isotopes. It is ... (TMB, DAB, 4-chloronapthol, etc.), as it ...
Biology Products: